Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Research & Development: 2014-2024

Historic Research & Development for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $101.6 million.

  • Viking Therapeutics' Research & Development rose 294.79% to $90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.5 million, marking a year-over-year increase of 144.06%. This contributed to the annual value of $101.6 million for FY2024, which is 59.30% up from last year.
  • Viking Therapeutics' Research & Development amounted to $101.6 million in FY2024, which was up 59.30% from $63.8 million recorded in FY2023.
  • Over the past 5 years, Viking Therapeutics' Research & Development peaked at $101.6 million during FY2024, and registered a low of $31.9 million during FY2020.
  • Over the past 3 years, Viking Therapeutics' median Research & Development value was $63.8 million (recorded in 2023), while the average stood at $73.2 million.
  • Data for Viking Therapeutics' Research & Development shows a peak YoY soared of 59.30% (in 2024) over the last 5 years.
  • Viking Therapeutics' Research & Development (Yearly) stood at $31.9 million in 2020, then skyrocketed by 40.87% to $45.0 million in 2021, then increased by 20.57% to $54.2 million in 2022, then climbed by 17.65% to $63.8 million in 2023, then spiked by 59.30% to $101.6 million in 2024.